- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
A Case of Drug-Induced Stevens-Johnson Syndrome With Primarily Visceral Involvement (San Diego Convention Center, Area K (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6014;
Despite causative drug withdrawal, prompt immunosuppression, and aggressive supportive measures, our patient did not recover. Her case demonstrates the importance of rapid diagnosis and a multi-disciplinary perspective to provide optimal patient outcomes.
- |||||||||| Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen, Rituxan (rituximab) / Roche
A Broken Brain (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5933;
She is now decannulated but continues to have catatonia. Early diagnosis for autoimmune encephalitis should always be considered in young females who present with psychosis and neurological symptoms with no prior history of mental disorders.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
A Real-world Experience on New Starts Versus Biological Switchers for Tezepelumab in Severe Asthma (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5731;
Our cohort suggests that new tezepelumab starts tended to have more non-T2 inflammation characteristics (comorbidities, OCS dependence and biomarkers) than those switched from another biologic agent. These study findings highlight current practice patterns, however given the broad mechanism of action (such as application in T2 high asthma) of tezepelumab can be considered even when selecting biologics for patients with SA as the first line agent.
- |||||||||| Effect of Biologics on Biomarkers of Type 2 Inflammation in Asthma: A Review of the Literature (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5728;
Tezepelumab impacted nearly all biomarkers, and dupilumab impacted many biomarkers but had no effect on blood or tissue eosinophils, with no reported outcomes for IL-5. Benralizumab and mepolizumab showed the greatest reductions in BEC and reduced tissue and sputum eosinophils, while omalizumab substantially reduced IgE and modestly reduced many other biomarkers.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Real-world Experience With Tezepelumab for Severe Asthma in an Academic Medical Center (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5722;
05). ConclusionsIn our real-world analysis, tezepelumab was effective for patients with severe asthma and resulted in fewer clinically significant exacerbations in the year after treatment initiation compared to the 12 months prior to treatment.
- |||||||||| astegolimab (RG 6149) / Amgen, Roche
Safety Profile of Astegolimab, An Anti-ST2 Antibody: A Systematic Review (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5717;
P2, P2b
These findings warrant further investigation. Astegolimab has been shown to be well tolerated in over 580 patients with asthma, atopic dermatitis, COPD, or COVID-19 pneumonia, with no safety concerns identified.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Effect of Tezepelumab on Exercise Tolerance in Patients With Severe, Uncontrolled Asthma From the NAVIGATOR Study (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5715;
P3
A greater proportion of tezepelumab recipients than placebo recipients reported improvements in SGRQ exercise tolerance items at week 24 (the first time point assessed) and week 52; this was observed across all items assessed. These data further support the efficacy of tezepelumab in improving asthma symptoms and health-related quality of life in a broad population of patients with severe, uncontrolled asthma.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Efficacy of Tezepelumab in Black or African American Patients: A Pooled Analysis of The PATHWAY and NAVIGATOR Studies (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5711;
P2, P3, P4
The small sample size of BAA patients limited the precision in estimating the treatment effect of tezepelumab, particularly with ACQ-6 score changes. Further studies, such as the ongoing phase 4 PASSAGE study (NCT05329194) that will enroll larger numbers of BAA patients, would be valuable to describe the clinical outcomes of tezepelumab treatment in this patient population.
- |||||||||| Use of Biologics and Asthma Remission in Underrepresented Patient Populations (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5710;
By identifying individuals benefiting from specific biologic therapy, more patients with severe asthma may attain disease control and be started on the biologic most likely to benefit them. This is particularly critical for the vulnerable asthma patients from underrepresented populations.
- |||||||||| Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
ANCA Vasculitis Presenting With Diffuse Alveolar Hemorrhage (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5676;
Also, C5a receptor inhibitor avacopan was also utilized as an add-on therapy. This highlights the importance of recognizing the diagnosis and initiating the appropriate therapy in a timely manner.
- |||||||||| A Case of Idiopathic Pneumonia Syndrome in a Patient With Recent Stem Cell Transplant (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5651;
Early recognition and intervention are crucial for achieving favorable outcomes in these challenging cases. This also highlights the importance of treating possible infectious etiologies while awaiting workup and when unable to rule out certain infections.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Xolair (omalizumab) / Roche, Novartis
A Combination of Tezepelumab and Omalizumab for Severe Persistent Asthma (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5640;
A while Later she was started on Azathioprine and Theophylline which showed a good effect with decreased exacerbations...Subsequently, she was desensitized to IV hydrocortisone which helped in managing her acute exacerbations, and then desensitized to oral prednisolone and kept on it chronically which helped in preventing her exacerbations...DiscussionSince Tezepelumab was added to the regimen along with Omalizumab, the patient had fewer exacerbations to 2 times/year compared to the previous year with 6 exacerbations. Theophylline was stopped completely, and prednisolone was tapered to 5 mg daily, hoping that it could be stopped completely in the near future.
- |||||||||| ketamine / Generic mfg.
Ketamine Chronicles: A Breath of Fresh Air in Status Asthmaticus (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5639;
This patient's subsequent improvement in respiratory symptoms and vital sign stabilization is evidence of ketamine's therapeutic potential in managing refractory status asthmaticus. While this case lends support to the growing interest in ketamine as a treatment option, further studies, and clinical trials are essential to fully assess its efficacy and safety and to identify potential target populations.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Psoriasiform Dermatitis During Dupilumab Treatment in Asthma and Allergic Bronchopulmonary Aspergillosis (ABPA) (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5633;
She was switched to voriconazole and omalizumab was eventually added...The ABPA again flared and mepolizumab was begun without success...The plaque psoriasis has since required Apremilast for control...An already upregulated IL-17/IL-23 cytokine milieu in the setting of active chronic co-infections in both cases may have further predisposed this shift during time of dupilumab therapy. Future considerations for therapy may involve targeting upstream to inhibit both Th2 and Th17 pathways, such as Tezepelumab.
- |||||||||| Xolair (omalizumab) / Roche, Novartis
Life-threatening Mast Cell Activation and Anaphylaxis in Mast Cell Leukemia and the Role of Omalizumab (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5632;
Despite intramuscular epinephrine, diphenhydramine, cetirizine, famotidine and dexamethasone, he remained symptomatic, requiring an epinephrine drip and escalating supplemental oxygen...He was treated sequentially with avapritinib, cladribine, imatinib and midostaurin without response...Chemotherapy with a six-day course of CLAG-M (Filgrastim, Cladribine, Cytrabine and Mixoxantrone (only G-CSF component) was initiated to reduce mast cell burden...Chemotherapy to decrease mast cell burden may potentially be combined with Omalizumab to improve MAS and prevent anaphylaxis, although this strategy remains anecdotal. However, barriers to inpatient treatment with medications restricted to outpatient use are myriad.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Xolair (omalizumab) / Roche, Novartis
Hyperimmunoglobulin E Syndrome: A Rare Autoimmune Masquerade of Th2 Asthma (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5629;
Dupilumab, an anti-IL4 and IL3 monoclonal antibody, was then used and the patient had control of asthma symptoms, and a decline in serum IgE levels. This case demonstrates a rare autoimmune masquerade of Th2 asthma while also demonstrating novel treatments with biologics.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
An Example of Tezepelumab Used to Treat Occupational Asthma (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5626;
This case shows that tezepelumab may be a viable treatment option in patients with OA. Further study of biologics in OA is warranted.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Association Between Bronchial Asthma and TSLP Gene Polymorphism: A Systematic Review and Meta-analysis (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5615;
This meta-analysis shows that the SNP rs2289278 has a protective effect on the development of asthma; whereas rs3806933 has a risk of asthma. Additionally, this study adds genomic-based support to the recent FDA approval of tezepelumab, an anti-TSLP agent.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Fasenra (benralizumab) / AstraZeneca
Biologics for Severe Asthma in Patients With Asthma-Chronic Obstructive Pulmonary Disease Overlap (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5607;
These results suggest that biologics are effective for severe asthma in ACO patients. Therefore, physicians should carefully evaluate the severity of asthma in ACO patients and provide treatment with biologics if necessary.
- |||||||||| Neulasta (pegfilgrastim) / Roche
A Very Rare Case of Endobronchial Obstruction Secondary to Breast Cancer Metastasis (San Diego Convention Center, Area J (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_4507;
The 5-year survival rate of breast cancer patients who recurred with distant metastasis is less than 20%. Our case emphasizes the importance of a high clinical suspicion of endobronchial metastasis in any patient with breast cancer who presents with clinical or radiological findings
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Nocardia as a Cause of Non-Resolving Pneumonia and Uncontrolled Asthma in a Patient on Biologics (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_4096;
This was seen in our case of a 49-year-old male with uncontrolled asthma treated with a monthly injection of Dupixent initially and then switched to Tezepelumab-ekko (TEK)...TMP-SMX caused an allergic reaction in the patient and the antibiotics management had to change awaiting sensitivities...Our case highlights the importance of considering immunomodulatory medications as a cause of opportunistic infections when formulating a differential diagnosis. We encourage reporting of similar cases to help in identifying associations with immunomodulatory medications and opportunistic infections since the use of biologics for asthma control is becoming a new approach to treatment.
- |||||||||| Prolia (denosumab) / Amgen, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Coronavirus-19 (COVID-19) and Hypercalcemic Crisis: A Rare Case Report (San Diego Convention Center, Area L (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3347;
Case Presentation: A 91-year-old female, with no co-morbidities, diagnosed with COVID-19 four days earlier and treated with Ritonavir and Nirmatrelvir (Paxlovid), was referred from a nursing facility due to sudden altered mentation and hypotension...The patient was treated with subcutaneous calcitonin, subcutaneous Denosumab, and IV fluids, resulting in improved mentation and overall clinical status within 48 hours...Potential pathogenic mechanisms include virus-induced calcium channel alterations and dysregulated immunity through cytokine storm, disrupting calcium homeostasis. We recommend prompt recognition and management of hypercalcemia in COVID-19 as well as the involvement of relevant subspecialties to prevent fatal outcomes.
- |||||||||| hydralazine hydrochloride / Generic mfg.
Community Acquired Pneumonia or Hydralazine-Induced Vasculitis - A Clinical Dilemma (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1586;
The patient was discharged home on prednisone with possible plans for initiating Avacopan...It is crucial to identify it and immediately stop hydralazine to prevent further damage. Depending on the severity of the vasculitis, patients may require treatment with immunosuppressive therapy especially if there is renal involvement.
- |||||||||| Orencia (abatacept) / BMS, Enbrel (etanercept) / Pfizer, Amgen
Milky Way of the Thorax: A Unique Case of Chylothorax in Seropositive Rheumatoid Arthritis (San Diego Convention Center, Area C (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1478;
Our patient's chylothorax fit some characteristics of a true RA-associated pleural effusion (low pH, low glucose, and elevated LDH), but additionally fit the diagnostic criteria for true chylothorax with triglycerides > 110 mg/dL. Interestingly, our patient had a triglyceride level > 200, which is not typically seen in cases of chylothorax, further underscoring the distinctive nature of our case.
- |||||||||| RLY-5836 / Relay Therap
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors (clinicaltrials.gov) - Feb 20, 2024
P1, N=265, Active, not recruiting,
Suspended --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Jul 2024 | Trial primary completion date: Dec 2025 --> Jun 2024
|
